Posts tagged TC Heartland.
Blogs
3 minute read
Since the enactment of the Hatch-Waxman Act in 1984, courts have held that brand companies can sue generics wherever they plan on making sales, which is everywhere in the U.S. In practice, most suits have been filed in Delaware and New Jersey, with suits against multiple generic companies over the same drug consolidated in one proceeding.
In November 2020, the Federal Circuit upended this settled practice when it issued its opinion in Valeant Pharmaceuticals v. Mylan Pharmaceuticals, No. 19-2402 (Fed. Cir. 2020), holding that venue is not established by contemplated future acts of ...
Blog Editors
Recent Updates
- Watch: DOJ’s New Self-Disclosure Rules: Decide Fast or Lose the Credit – Speaking of Litigation
- AI Medical Technology Meets IP Law in Patent Infringement Suit
- DOJ Civil Division Announces Accelerated Review of FCA Whistleblower Complaints Involving Federally Funded, State-Administered Benefits Programs
- Washington Amends CEMA: Plaintiffs Rush to File Actions Before June 11, 2026 Effective Date
- Five Cases Health Care and Life Sciences GCs Should Keep Watching in 2026